These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 31706956)

  • 1. Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors.
    Deacon CF
    Peptides; 2020 Mar; 125():170196. PubMed ID: 31706956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
    Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
    Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes.
    Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Yokoyama H; Haneda M
    Front Endocrinol (Lausanne); 2020; 11():214. PubMed ID: 32390941
    [No Abstract]   [Full Text] [Related]  

  • 4. DPP-4 inhibition increases GIP and decreases GLP-1 incretin effects during intravenous glucose tolerance test in Wistar rats.
    Freyse EJ; Berg S; Kohnert KD; Heinke P; Salzsieder E
    Biol Chem; 2011 Mar; 392(3):209-15. PubMed ID: 21281062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.
    Deacon CF; Wamberg S; Bie P; Hughes TE; Holst JJ
    J Endocrinol; 2002 Feb; 172(2):355-62. PubMed ID: 11834453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
    Green BD; Gault VA; O'Harte FP; Flatt PR
    Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of GIP and pancreatic GLP-1 in the glucoregulatory effect of DPP-4 inhibition in mice.
    Hutch CR; Roelofs K; Haller A; Sorrell J; Leix K; D'Alessio DD; Augustin R; Seeley RJ; Klein T; Sandoval DA
    Diabetologia; 2019 Oct; 62(10):1928-1937. PubMed ID: 31414143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
    Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
    Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.
    McKillop AM; Duffy NA; Lindsay JR; Green BD; Patterson S; O'Harte FP; Bell PM; Flatt PR
    Eur J Endocrinol; 2009 Dec; 161(6):877-85. PubMed ID: 19755410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in β-Cell Function in Patients With Type 2 Diabetes.
    Stensen S; Gasbjerg LS; Rosenkilde MM; Vilsbøll T; Holst JJ; Hartmann B; Christensen MB; Knop FK
    Diabetes; 2022 Oct; 71(10):2209-2221. PubMed ID: 35796651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing incretin action for the treatment of type 2 diabetes.
    Drucker DJ
    Diabetes Care; 2003 Oct; 26(10):2929-40. PubMed ID: 14514604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
    Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
    Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
    Green BD; Flatt PR; Bailey CJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: A narrative review.
    Mima A; Nomura A; Fujii T
    Biomed Pharmacother; 2023 Sep; 165():115032. PubMed ID: 37331253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
    Kieffer TJ; McIntosh CH; Pederson RA
    Endocrinology; 1995 Aug; 136(8):3585-96. PubMed ID: 7628397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
    Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
    Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.